Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Are you Dr. Lenzi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Renato Lenzi, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is an Associate Professor of Medicine at University Tex Houston.
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1990
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1983 - 1986
- One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1980 - 1983
- University of Cattolica del Sacro CuoreClass of 1977
Certifications & Licensure
- FL State Medical License 2021 - Present
- NJ State Medical License 1986 - Present
- AZ State Medical License 2023 - 2026
- TX State Medical License 1990 - 2026
- WA State Medical License 2023 - 2026
- AL State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- Join now to see all
Publications & Presentations
PubMed
- 72 citationsEstrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular CarcinomaManal Hassan, Gehan Botrus, Reham Abdel-Wahab, Robert A. Wolff, Donghui Li
Clinical Gastroenterology and Hepatology. 2017-11-01 - 18 citationsOccult primary, version 3.2014; Featured updates to the NCCN guidelinesDavid S. Ettinger, Charles R. Handorf, Mark Agulnik, Daniel W. Bowles, Justin M M Cates
Journal of the National Comprehensive Cancer Network. 2014-07-01 - 6 citationsA phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.Heather R. Carlson, Renato Lenzi, Martin N. Raber, Gauri R. Varadhachary
International Journal of Clinical Oncology. 2013-04-01